CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

CVS Health exceeded Q4 sales estimates with $97.71B revenue. The company projects 2025 revenue above $134B and expects Medicare Advantage margins to improve.

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

This was the stock's second consecutive day of losses.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

So, even beyond CVS Health's poor financial results, the guidance cuts are contributing to the terrible stock market performance the healthcare giant has posted in recent years.

Jefferies analyst Brian Tanquilut maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $69.00. Brian Tanquilut has given his Buy rating due to a ...

CVS Health stock surged over 11% following a sizable revenue beat and the appointment of new CEO David Joyner. See why I'm recommending a Buy on CVS stock.

On Wednesday, CVS Health Corp (NYSE:CVS) reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion. Total revenues increased 4.2%, driven by growth in the Health ...